Arthritis, Rheumatoid Clinical Trial
— contRAst XOfficial title:
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Verified date | January 2024 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RA is a chronic, systemic inflammatory autoimmune disease which requires treatment for a long time period, hence it is important to study the long-term safety and efficacy of the continuous treatment with GSK3196165 over several years. This is a Phase 3, multicenter, parallel group treatment and long-term extension study primarily to assess safety with efficacy assessment as a secondary objective. Adult participants with RA who have completed the treatment phase of a qualifying GSK3196165 clinical studies (Phase 3 studies contRAst 1 (201790: NCT03980483), contRAst 2 (201791: NCT03970837) and contRAst 3 (202018: NCT04134728) and who, in investigator's judgement will benefit from extended treatment with GSK3196165 will be included in this study (contRAst X [209564: NCT04333147]). Participants will continue to receive the same background conventional synthetic disease modifying anti-rheumatic drug(s) [csDMARD(s)] treatment as they received in their qualifying study. Eligible participants will be enrolled to receive weekly GSK3196165 90 milligrams (mg) or 150 mg by subcutaneous (SC) injection. The anticipated study duration is approximately 4 years which will enable participants to receive treatment with GSK3196165 until it is expected to become commercially available. Approximately 3000 participants from the qualifying studies will participate in this long-term extension study
Status | Terminated |
Enrollment | 2916 |
Est. completion date | February 24, 2023 |
Est. primary completion date | February 24, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants with rheumatoid arthritis who are aged >=18 years at the time of signing informed consent, who have completed one of the qualifying GSK3196165 clinical studies and who, in the opinion of the investigator, may benefit from treatment with GSK3196165. - Body weight >=40 kilograms (kg). - Male or female participants are eligible to participate as long as they meet the contraceptive eligibility criteria and agree to abide by the contraceptive requirements. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - For participants on methotrexate (MTX): must be willing to continue treatment with oral folic acid (at least 5 mg/week) or equivalent while receiving MTX (mandatory co-medication for MTX treatment). Exclusion Criteria: - Had study intervention permanently discontinued at any time during a qualifying study except any participant with a new diagnosis of latent Mycobacterium tuberculosis (TB) at the end of study assessment in a qualifying study and currently undertaking or willing to complete at least 4 weeks of anti-TB treatment off study treatment, per world health organization (WHO) or national guidelines prior to re-commencing therapy and complete the remainder of anti-TB treatment while on study. - Evidence of latent TB (as documented by a positive QuantiFERON-TB Gold plus test or T-SPOT.TB test, no findings on medical history or clinical examination consistent with active TB, and a normal chest radiograph) except for participants that - Are currently undertaking or willing to complete at least 4 weeks of anti-TB therapy off study treatment, as per WHO or national guidelines prior to re- commencing study treatment and agree to complete the remainder of anti-TB treatment while in the study or - Had documented evidence of satisfactory anti-TB treatment as per WHO or national guidelines following review by a physician specializing in TB on entry to a qualifying study. - Current or previous active TB regardless of treatment. - Were temporarily discontinued from study intervention at the time of the final study visit of a qualifying study and, in the opinion of the investigator, participation in the extension study poses an unacceptable risk for the participant's participation. - A new cancer or malignancy except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured by the investigator. - Have developed any lymphoproliferative disorder during a qualifying study, such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, or signs and symptoms suggestive of current lymphatic disease. - Have significant uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neuropsychiatric disorders, or abnormal laboratory values that developed during a qualifying study that, in the opinion of the investigator, poses an unacceptable risk for the participant's participation. - Participants who are expected to be non-compliant with restrictions on medications and vaccinations prior to the study, during the study or during the 8-week safety follow-up of the study. - Participants who are currently participating in any interventional clinical study other than a qualifying GSK3196165 clinical study. - Abnormal chest radiograph within the last 12 weeks judged by the investigator as clinically-significant. - Pregnant or lactating, or women planning to become pregnant or initiating breastfeeding. - History of sensitivity to any of the study treatments, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. |
Country | Name | City | State |
---|---|---|---|
Argentina | GSK Investigational Site | Buenos Aires | |
Argentina | GSK Investigational Site | Ciudad Autonoma Buenos Aires | |
Argentina | GSK Investigational Site | Ciudad Autonoma Buenos aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autonoma Buenos Aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autonoma Buenos Aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autonoma Buenos Aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Argentina | GSK Investigational Site | Ciudad Autónoma de Buenos Aires | |
Argentina | GSK Investigational Site | Cordoba | |
Argentina | GSK Investigational Site | Cordoba | Córdova |
Argentina | GSK Investigational Site | La Palta | Buenos Aires |
Argentina | GSK Investigational Site | Mar del Plata | Buenos Aires |
Argentina | GSK Investigational Site | Nueva Cordoba | |
Argentina | GSK Investigational Site | Quilmes | Buenos Aires |
Argentina | GSK Investigational Site | Rosario | Santa Fe |
Argentina | GSK Investigational Site | Salta | |
Argentina | GSK Investigational Site | San Isidro | Buenos Aires |
Argentina | GSK Investigational Site | San Juan | |
Argentina | GSK Investigational Site | San Miguel de Tucuman | Tucumán |
Argentina | GSK Investigational Site | San Miguel de Tucumán | Tucumán |
Argentina | GSK Investigational Site | San Nicolas | Buenos Aires |
Australia | GSK Investigational Site | Gold Coast | Queensland |
Australia | GSK Investigational Site | Woodville | South Australia |
Belgium | GSK Investigational Site | Mons | |
Bulgaria | GSK Investigational Site | Blagoevgrad | |
Bulgaria | GSK Investigational Site | Pleven | |
Bulgaria | GSK Investigational Site | Plovdiv | |
Bulgaria | GSK Investigational Site | Ruse | |
Bulgaria | GSK Investigational Site | Sevlievo | |
Bulgaria | GSK Investigational Site | Sofia | |
Bulgaria | GSK Investigational Site | Sofia | |
Bulgaria | GSK Investigational Site | Sofia | |
Bulgaria | GSK Investigational Site | Sofia | |
Bulgaria | GSK Investigational Site | Vidin | |
Canada | GSK Investigational Site | Brampton | Ontario |
Canada | GSK Investigational Site | Trois-Rivieres | Quebec |
China | GSK Investigational Site | Baotou | Inner Mongolia |
China | GSK Investigational Site | Beijing | |
China | GSK Investigational Site | Beijing | |
China | GSK Investigational Site | Bengbu | Anhui |
China | GSK Investigational Site | Changchun | Jilin |
China | GSK Investigational Site | Changsha | Hunan |
China | GSK Investigational Site | Chengdu | Sichuan |
China | GSK Investigational Site | Guangzhou | |
China | GSK Investigational Site | Guilin | Guangxi |
China | GSK Investigational Site | Hangzhou | |
China | GSK Investigational Site | Huzhou | Zhejiang |
China | GSK Investigational Site | Jinzhou | Liaoning |
China | GSK Investigational Site | Nanchang, | Jiangxi |
China | GSK Investigational Site | Nanjing | |
China | GSK Investigational Site | Pingxiang | Jiangxi |
China | GSK Investigational Site | Shanghai | |
China | GSK Investigational Site | Shijiazhuang | Hebei |
China | GSK Investigational Site | Taizhou | Jiangsu |
China | GSK Investigational Site | Tianjin | |
China | GSK Investigational Site | Tongliao | Inner Mongolia |
China | GSK Investigational Site | Wuhan | Hubei |
China | GSK Investigational Site | Xuzhou | Jiangsu |
China | GSK Investigational Site | Yangzhou | |
China | GSK Investigational Site | Yanji | |
China | GSK Investigational Site | ZhuZhou | Hunan |
Colombia | GSK Investigational Site | Barranquilla | |
Colombia | GSK Investigational Site | Barranquilla | |
Colombia | GSK Investigational Site | Bogotá | |
Colombia | GSK Investigational Site | Bucaramanga | |
Czechia | GSK Investigational Site | Brno | |
Czechia | GSK Investigational Site | Brno | |
Czechia | GSK Investigational Site | Ostrava | |
Czechia | GSK Investigational Site | Praha 10 | |
Czechia | GSK Investigational Site | Praha 11 | |
Czechia | GSK Investigational Site | Praha 2 | |
Czechia | GSK Investigational Site | Praha 4 | |
Czechia | GSK Investigational Site | Praha 4 Nusle | |
Czechia | GSK Investigational Site | Praha 5 | |
Czechia | GSK Investigational Site | Uherske Hradiste | |
Czechia | GSK Investigational Site | Zlin | |
Estonia | GSK Investigational Site | Parnu | |
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tartu | |
Estonia | GSK Investigational Site | Tartu | |
Germany | GSK Investigational Site | Dresden | Sachsen |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Magdeburg | |
Germany | GSK Investigational Site | Rendsburg | Schleswig-Holstein |
Hungary | GSK Investigational Site | Baja | |
Hungary | GSK Investigational Site | Balatonfured | |
Hungary | GSK Investigational Site | Budapest | |
Hungary | GSK Investigational Site | Budapest | |
Hungary | GSK Investigational Site | Szekesfehervar | |
Hungary | GSK Investigational Site | Székesfehérvár | |
Hungary | GSK Investigational Site | Szentes | |
Hungary | GSK Investigational Site | Veszprem | |
India | GSK Investigational Site | Ahmedabad | |
India | GSK Investigational Site | Ahmedabad | |
India | GSK Investigational Site | Belagavi | |
India | GSK Investigational Site | Hubli | |
India | GSK Investigational Site | Hyderabad | |
India | GSK Investigational Site | Jaipur | |
India | GSK Investigational Site | Jaipur | |
India | GSK Investigational Site | Kolkata | |
India | GSK Investigational Site | Nagpur | |
India | GSK Investigational Site | Nagpur | |
India | GSK Investigational Site | New Delhi | |
India | GSK Investigational Site | Pune | |
India | GSK Investigational Site | Surat | |
Japan | GSK Investigational Site | Aichi | |
Japan | GSK Investigational Site | Aichi | |
Japan | GSK Investigational Site | Aichi | |
Japan | GSK Investigational Site | Chiba | |
Japan | GSK Investigational Site | Chiba | |
Japan | GSK Investigational Site | Chiba | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Hiroshima | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hyogo | |
Japan | GSK Investigational Site | Hyogo | |
Japan | GSK Investigational Site | Ibaraki | |
Japan | GSK Investigational Site | Kagawa | |
Japan | GSK Investigational Site | Kagoshima | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kochi | |
Japan | GSK Investigational Site | Kochi | |
Japan | GSK Investigational Site | Kumamoto | |
Japan | GSK Investigational Site | Miyagi | |
Japan | GSK Investigational Site | Miyagi | |
Japan | GSK Investigational Site | Nagano | |
Japan | GSK Investigational Site | Nagasaki | |
Japan | GSK Investigational Site | Nagasaki | |
Japan | GSK Investigational Site | Nagasaki | |
Japan | GSK Investigational Site | Niigata | |
Japan | GSK Investigational Site | Niigata | |
Japan | GSK Investigational Site | Okayama | |
Japan | GSK Investigational Site | Okayama | |
Japan | GSK Investigational Site | Okayama | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Wakayama | |
Japan | GSK Investigational Site | Yamaguchi | |
Korea, Republic of | GSK Investigational Site | Anyang-Si | |
Korea, Republic of | GSK Investigational Site | Cheonan-si | |
Korea, Republic of | GSK Investigational Site | Daegu | |
Korea, Republic of | GSK Investigational Site | Gwangju | |
Korea, Republic of | GSK Investigational Site | Incheon | |
Korea, Republic of | GSK Investigational Site | Seongnam-si | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Suwon-si, Gyeonggi-do | |
Latvia | GSK Investigational Site | Adazi | |
Latvia | GSK Investigational Site | Liepaja | |
Lithuania | GSK Investigational Site | Kaunas | |
Lithuania | GSK Investigational Site | Kaunas | |
Lithuania | GSK Investigational Site | Klaipeda | |
Lithuania | GSK Investigational Site | Siauliai | |
Lithuania | GSK Investigational Site | Vilnius | |
Malaysia | GSK Investigational Site | Klang | |
Malaysia | GSK Investigational Site | Kuala Lumpur | |
Malaysia | GSK Investigational Site | Seremban, Negeri Sembilan | |
Malaysia | GSK Investigational Site | Sibu | |
Mexico | GSK Investigational Site | Durango | |
Mexico | GSK Investigational Site | Guadalajara | Jalisco |
Mexico | GSK Investigational Site | Guadalajara | Jalisco |
Mexico | GSK Investigational Site | Leon | Guanajuato |
Mexico | GSK Investigational Site | Merida | Yucatán |
Mexico | GSK Investigational Site | Mexicali | Baja California Sur |
Mexico | GSK Investigational Site | Mexico | |
Mexico | GSK Investigational Site | Mexico City | Durango |
Mexico | GSK Investigational Site | San Luis Potosí | |
Poland | GSK Investigational Site | Bialystok | |
Poland | GSK Investigational Site | Bialystok | |
Poland | GSK Investigational Site | Bydgoszcz | |
Poland | GSK Investigational Site | Bydgoszcz | |
Poland | GSK Investigational Site | Czestochowa | |
Poland | GSK Investigational Site | Elblag | |
Poland | GSK Investigational Site | Gdansk | |
Poland | GSK Investigational Site | Gdynia | |
Poland | GSK Investigational Site | Gdynia | |
Poland | GSK Investigational Site | Grodzisk Mazowiecki | |
Poland | GSK Investigational Site | Katowice | |
Poland | GSK Investigational Site | Katowice | |
Poland | GSK Investigational Site | Krakow | |
Poland | GSK Investigational Site | Krakow | |
Poland | GSK Investigational Site | Kraków | |
Poland | GSK Investigational Site | Lodz | |
Poland | GSK Investigational Site | Lodz | |
Poland | GSK Investigational Site | Lublin | |
Poland | GSK Investigational Site | Lublin | |
Poland | GSK Investigational Site | Nowa Sol | |
Poland | GSK Investigational Site | Olsztyn | |
Poland | GSK Investigational Site | Poznan | |
Poland | GSK Investigational Site | Poznan | |
Poland | GSK Investigational Site | Poznan | |
Poland | GSK Investigational Site | Poznan | |
Poland | GSK Investigational Site | Siedlce | |
Poland | GSK Investigational Site | Sochaczew | |
Poland | GSK Investigational Site | Staszow | |
Poland | GSK Investigational Site | Torun | |
Poland | GSK Investigational Site | Warsaw | |
Poland | GSK Investigational Site | Warszawa | |
Poland | GSK Investigational Site | Warszawa | |
Poland | GSK Investigational Site | Warszawa | |
Poland | GSK Investigational Site | Warszawa | |
Poland | GSK Investigational Site | Warszawa | |
Poland | GSK Investigational Site | Wroclaw | |
Poland | GSK Investigational Site | Wroclaw | |
Poland | GSK Investigational Site | Zamosc | |
Russian Federation | GSK Investigational Site | Ekaterinburg | |
Russian Federation | GSK Investigational Site | Ekaterinburg | |
Russian Federation | GSK Investigational Site | Kemerovo | |
Russian Federation | GSK Investigational Site | Kemerovo | |
Russian Federation | GSK Investigational Site | Korolev | |
Russian Federation | GSK Investigational Site | Krasnoyarsk | |
Russian Federation | GSK Investigational Site | Moscow | |
Russian Federation | GSK Investigational Site | Moscow | |
Russian Federation | GSK Investigational Site | Moscow | |
Russian Federation | GSK Investigational Site | Novosibirsk | |
Russian Federation | GSK Investigational Site | Novosibirsk | |
Russian Federation | GSK Investigational Site | Omsk | |
Russian Federation | GSK Investigational Site | Saint Petersburg | |
Russian Federation | GSK Investigational Site | Saint-Petersburg | |
Russian Federation | GSK Investigational Site | Saratov | |
Russian Federation | GSK Investigational Site | Smolensk | |
Russian Federation | GSK Investigational Site | Tomsk | |
Russian Federation | GSK Investigational Site | Tver | |
Russian Federation | GSK Investigational Site | Ulyanovsk | |
Russian Federation | GSK Investigational Site | Yaroslavl | |
Russian Federation | GSK Investigational Site | Yaroslavl | |
Russian Federation | GSK Investigational Site | Yaroslavl | |
Serbia | GSK Investigational Site | Belgrade | |
South Africa | GSK Investigational Site | Bellville | |
South Africa | GSK Investigational Site | Bloemfontein | |
South Africa | GSK Investigational Site | Cape Town | |
South Africa | GSK Investigational Site | Cape Town | |
South Africa | GSK Investigational Site | Durban | KwaZulu- Natal |
South Africa | GSK Investigational Site | Johannesburg | |
South Africa | GSK Investigational Site | Johannesburg | |
South Africa | GSK Investigational Site | Kempton Park | |
South Africa | GSK Investigational Site | Pretoria | |
South Africa | GSK Investigational Site | Pretoria | Gauteng |
South Africa | GSK Investigational Site | Somerset West | |
South Africa | GSK Investigational Site | Stellenbosch | |
Spain | GSK Investigational Site | Barcelona | |
Spain | GSK Investigational Site | Barcelona | |
Spain | GSK Investigational Site | Cordoba | |
Spain | GSK Investigational Site | Coruña | |
Spain | GSK Investigational Site | Elche | |
Spain | GSK Investigational Site | Santander | |
Spain | GSK Investigational Site | Santiago De Compostela. La Coruña. | |
Spain | GSK Investigational Site | Sevilla | |
Spain | GSK Investigational Site | Valencia | |
Thailand | GSK Investigational Site | Bangkok | |
Thailand | GSK Investigational Site | Rajathevee | |
Ukraine | GSK Investigational Site | Cherkasy | |
Ukraine | GSK Investigational Site | Ivano-Frankivsk | |
Ukraine | GSK Investigational Site | Kharkiv | |
Ukraine | GSK Investigational Site | Kharkiv | |
Ukraine | GSK Investigational Site | Kharkiv | |
Ukraine | GSK Investigational Site | Kyiv | |
Ukraine | GSK Investigational Site | Kyiv | |
Ukraine | GSK Investigational Site | Kyiv | |
Ukraine | GSK Investigational Site | Kyiv | |
Ukraine | GSK Investigational Site | Kyiv | |
Ukraine | GSK Investigational Site | Kyiv | |
Ukraine | GSK Investigational Site | Lutsk | |
Ukraine | GSK Investigational Site | Lutsk | |
Ukraine | GSK Investigational Site | Odessa | |
Ukraine | GSK Investigational Site | Poltava | |
Ukraine | GSK Investigational Site | Vinnytsia | |
Ukraine | GSK Investigational Site | Vinnytsia | |
Ukraine | GSK Investigational Site | Vinnytsia | |
Ukraine | GSK Investigational Site | Vinnytsia | |
Ukraine | GSK Investigational Site | Vinnytsya | |
Ukraine | GSK Investigational Site | Zaporizhzhia | |
Ukraine | GSK Investigational Site | Zaporizhzia | |
Ukraine | GSK Investigational Site | Zhytomyr | |
United Kingdom | GSK Investigational Site | Coventry | |
United Kingdom | GSK Investigational Site | Northwood | Middlesex |
United Kingdom | GSK Investigational Site | Orpington | Kent |
United States | GSK Investigational Site | Amarillo | Texas |
United States | GSK Investigational Site | Anniston | Alabama |
United States | GSK Investigational Site | Atlanta | Georgia |
United States | GSK Investigational Site | Austin | Texas |
United States | GSK Investigational Site | Austin | Texas |
United States | GSK Investigational Site | Aventura | Florida |
United States | GSK Investigational Site | Baytown | Texas |
United States | GSK Investigational Site | Bowling Green | Kentucky |
United States | GSK Investigational Site | Brandon | Florida |
United States | GSK Investigational Site | Brooklyn | New York |
United States | GSK Investigational Site | Cincinnati | Ohio |
United States | GSK Investigational Site | Clearwater | Florida |
United States | GSK Investigational Site | Colleyville | Texas |
United States | GSK Investigational Site | Covina | California |
United States | GSK Investigational Site | Dallas | Texas |
United States | GSK Investigational Site | Daytona Beach | Florida |
United States | GSK Investigational Site | Denver | Colorado |
United States | GSK Investigational Site | Evansville | Indiana |
United States | GSK Investigational Site | Fayetteville | North Carolina |
United States | GSK Investigational Site | Flagstaff | Arizona |
United States | GSK Investigational Site | Fort Collins | Colorado |
United States | GSK Investigational Site | Freehold | New Jersey |
United States | GSK Investigational Site | Gilbert | Arizona |
United States | GSK Investigational Site | Glendale | Arizona |
United States | GSK Investigational Site | Glendale | Wisconsin |
United States | GSK Investigational Site | Grand Blanc | Michigan |
United States | GSK Investigational Site | Greensboro | North Carolina |
United States | GSK Investigational Site | Greenville | South Carolina |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Idaho Falls | Idaho |
United States | GSK Investigational Site | Jacksonville | Florida |
United States | GSK Investigational Site | Lake Charles | Louisiana |
United States | GSK Investigational Site | Lansing | Michigan |
United States | GSK Investigational Site | Lebanon | New Hampshire |
United States | GSK Investigational Site | Lincoln | Nebraska |
United States | GSK Investigational Site | Lubbock | Texas |
United States | GSK Investigational Site | Marietta | Georgia |
United States | GSK Investigational Site | Mesa | Arizona |
United States | GSK Investigational Site | Miami | Florida |
United States | GSK Investigational Site | Miami | Florida |
United States | GSK Investigational Site | Miami | Florida |
United States | GSK Investigational Site | Miami | Florida |
United States | GSK Investigational Site | Miami Lakes | Florida |
United States | GSK Investigational Site | Miami Lakes | Florida |
United States | GSK Investigational Site | Minot | North Dakota |
United States | GSK Investigational Site | Monroe | Louisiana |
United States | GSK Investigational Site | New Port Richey | Florida |
United States | GSK Investigational Site | Novi | Michigan |
United States | GSK Investigational Site | Oklahoma City | Oklahoma |
United States | GSK Investigational Site | Oklahoma City | Oklahoma |
United States | GSK Investigational Site | Oklahoma City | Oklahoma |
United States | GSK Investigational Site | Orlando | Florida |
United States | GSK Investigational Site | Palmetto Bay | Florida |
United States | GSK Investigational Site | Phoenix | Arizona |
United States | GSK Investigational Site | Phoenix | Arizona |
United States | GSK Investigational Site | Plano | Texas |
United States | GSK Investigational Site | Poway | California |
United States | GSK Investigational Site | Saint Louis | Missouri |
United States | GSK Investigational Site | San Diego | California |
United States | GSK Investigational Site | San Diego | California |
United States | GSK Investigational Site | Skokie | Illinois |
United States | GSK Investigational Site | Summerville | South Carolina |
United States | GSK Investigational Site | Tamarac | Florida |
United States | GSK Investigational Site | Tampa | Florida |
United States | GSK Investigational Site | Tampa | Florida |
United States | GSK Investigational Site | The Woodlands | Texas |
United States | GSK Investigational Site | Tomball | Texas |
United States | GSK Investigational Site | Tucson | Arizona |
United States | GSK Investigational Site | Upland | California |
United States | GSK Investigational Site | Van Nuys | California |
United States | GSK Investigational Site | Vandalia | Ohio |
United States | GSK Investigational Site | Waco | Texas |
United States | GSK Investigational Site | Wheaton | Maryland |
United States | GSK Investigational Site | Whittier | California |
United States | GSK Investigational Site | Wichita | Kansas |
United States | GSK Investigational Site | Yukon | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline | Iqvia Pty Ltd |
United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Estonia, Germany, Hungary, India, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Thailand, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death, cause life threatening events which requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability or incapacity and birth defect or congenital anomaly. Protocol defined AESIs were included. | Up to approximately 145 Weeks | |
Primary | Change From Baseline in Hematology Parameter of Platelet Count at Week 24 | Blood samples were collected for the assessment of change from baseline in hematology parameter platelet count. | Baseline (Day 01) and Week 24 | |
Primary | Change From Baseline in Hematology Parameter of Platelet Count at Week 48 | Blood samples were collected for the assessment of change from baseline in hematology parameter platelet count. | Baseline (Day 01) and Week 48 | |
Primary | Change From Baseline in Hematology Parameter of Platelet Count at Week 96 | Blood samples were collected for the assessment of change from baseline in hematology parameter platelet count. | Baseline (Day 01) and Week 96 | |
Primary | Change From Baseline in Hematology Parameter of Platelet Count at Week 144 | Blood samples were collected for the assessment of change from baseline in hematology parameter platelet count. | Baseline (Day 01) and Week 144 | |
Primary | Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 | Blood samples were collected for the assessment of change from baseline in hematology parameter hemoglobin. | Baseline (Day 01) and Week 24 | |
Primary | Change From Baseline in Hematology Parameter of Hemoglobin at Week 48 | Blood samples were collected for the assessment of change from baseline in hematology parameter hemoglobin. | Baseline (Day 01) and Week 48 | |
Primary | Change From Baseline in Hematology Parameter of Hemoglobin at Week 96 | Blood samples were collected for the assessment of change from baseline in hematology parameter hemoglobin. | Baseline (Day 01) and Week 96 | |
Primary | Change From Baseline in Hematology Parameter of Hemoglobin at Week 144 | Blood samples were collected for the assessment of change from baseline in hematology parameter hemoglobin. | Baseline (Day 01) and Week 144 | |
Primary | Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 24 | Blood samples were collected for the assessment of change from baseline in hematology parameters including White Blood Cell (WBC) Count with Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. | Baseline (Day 01) and Week 24 | |
Primary | Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 48 | Blood samples were collected for the assessment of change from baseline in hematology parameters including White Blood Cell (WBC) Count with Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. | Baseline (Day 01) and Week 48 | |
Primary | Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 96 | Blood samples were collected for the assessment of change from baseline in hematology parameters including White Blood Cell (WBC) Count with Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. | Baseline (Day 01) and Week 96 | |
Primary | Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 144 | Blood samples were collected for the assessment of change from baseline in hematology parameters including White Blood Cell (WBC) Count with Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. | Baseline (Day 01) and Week 144 | |
Primary | Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 24 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including AST, ALT, AP, GGT, CPK. | Baseline (Day 01) and Week 24 | |
Primary | Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 48 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including AST, ALT, AP, GGT, CPK. | Baseline (Day 01) and Week 48 | |
Primary | Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 96 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including AST, ALT, AP, GGT, CPK. | Baseline (Day 01) and Week 96 | |
Primary | Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 144 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including AST, ALT, AP, GGT, CPK. | Baseline (Day 01) and Week 144 | |
Primary | Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 24 | Blood samples was collected for the assessment of clinical chemistry parameters including Cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein-cholesterol (HDL), Triglycerides | Baseline (Day 01) and Week 24 | |
Primary | Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 48 | Blood samples was collected for the assessment of clinical chemistry parameters including Cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein-cholesterol (HDL), Triglycerides | Baseline (Day 01) and Week 48 | |
Primary | Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 96 | Blood samples was collected for the assessment of clinical chemistry parameters including Cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein-cholesterol (HDL), Triglycerides | Baseline (Day 01) and Week 96 | |
Primary | Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 144 | Blood samples was collected for the assessment of clinical chemistry parameters including Cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein-cholesterol (HDL), Triglycerides | Baseline (Day 01) and Week 144 | |
Primary | Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry Abnormalities | Number of participants with NCI-CTCAE >=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case >=Grade 3 shifts from Baseline. | Up to approximately 145 Weeks | |
Primary | Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 24 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including total bilirubin, direct bilirubin. | Baseline (Day 01) and Week 24 | |
Primary | Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 48 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including total bilirubin, direct bilirubin. | Baseline (Day 01) and Week 48 | |
Primary | Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 96 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including total bilirubin, direct bilirubin. | Baseline (Day 01) and Week 96 | |
Primary | Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 144 | Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters including total bilirubin, direct bilirubin. | Baseline (Day 01) and Week 144 | |
Secondary | Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score Lesser Than or Equal to (<=)10 (CDAI) Low Disease Activity (LDA) at Week 24, 48, 96 and 144 | Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10. Percentage values are rounded off. | Week 24, 48, 96 and 144 | |
Secondary | Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score <=2.8 (CDAI Remission) at Week 24, 48, 96 and 144 | Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score <=2.8. Percentage values are rounded off. | Week 24, 48, 96 and 144 | |
Secondary | Percentage of Participants Achieving Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) <2.6 at Week 24, 48, 96 and 144 | The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). PtGA is transformed to a 0-10 scale before computing the total score. DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement. Percentage values are rounded off. | Week 24, 48, 96 and 144 | |
Secondary | Percentage of Participants Achieving Disease Activity Score Using 28 Joint Count and Erythrocyte Sedimentation Rate (ESR) <2.6 (DAS28-ESR Remission) at Week 24, 48, 96 and 132 | The DAS28-ESR is a measure of RA disease activity calculated using TJC28,SJC28, ESR (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). PtGA is transformed to a 0-10 scale before computing the total score. DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement. Percentage values are rounded off. | Week 24, 48, 96 and 132 | |
Secondary | Percentage of Participants Achieving American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) Remission at Week 24, 48, 96 and 144 | Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) <= 1, Swollen Joint Count 66 (SJC66) <= 1, high sensitivity C-reactive Protein (hsCRP) <= 1mg/dl and patient's global assessment of disease activity (PtGA) <= 10. Simple Disease Activity Index based ACR/EULAR remission is achieved if a has SDAI <= 3.3. The SDAI is the sum of the tender/painful joint count and swollen joint count, employing 28 joints; PtGA and PhGA (on a scale of 0-10); and hsCRP (mg/L). Percentage values are rounded off. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values for Clinical Disease Activity Index (CDAI) Total Score | CDAI total score is a composite score consisting of the sum of TJC28, TJC28, PtGA (visual analogue scale with values from 0=best to 100=worst) and PhGA (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values for Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) | The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- PtGA is transformed to a 0-10 scale before computing the total score. CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values for Disease Activity Score Using 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) | The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter [mm]/hour[hr]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). PtGA is transformed to a 0-10 scale before computing the total score. DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. | Week 24, 48, 96 and 132 | |
Secondary | Absolute Values of Van Der Heijde Modified Total Sharp Scores (mTSS) | Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score ranges from 0 to 448 for mTSS with higher values representing higher disease activity. | Week 24 and 48 | |
Secondary | Absolute Values for Health Assessment Questionnaire Disability Index (HAQ-DI) | The HAQ-DI includes 20 questions which assesses difficulty in performing activities of daily living. The questionnaire assesses eight domains of physical functioning: Dressing and Grooming, Hygiene, Arising, Reach, Eating, Grip, Walking, Common Daily Activities. The questions assess domain scores ranging from 0 "without any difficulty" to 3 "unable to do." Scores on each domain were summed and averaged to provide an overall score ranging from 0 to 3, where higher score reflected worse status and a lower score indicates better quality of life. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values for Arthritis Pain Visual Analogue Scale (VAS) | For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values Short Form (SF)-36 Mental Component Scores (MCS) | SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health. Quality Metric software was used for scoring. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values SF-36 Domain Scores | Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. Quality Metric software was used for scoring for SF-36. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values SF-36 Physical Component Scores (PCS) | SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health. Quality Metric software was used for scoring. | Week 24, 48, 96 and 144 | |
Secondary | Absolute Values Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue | The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. | Week 24, 48, 96 and 144 | |
Secondary | Number of Participants With Anti-GSK3196165 Antibodies | Serum samples were collected for the determination of anti- GSK3196165 antibodies (ADA) using a validated electrochemiluminescence (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample. Additionally, confirmed positive ADA samples were also tested in a validated neutralizing antibody assay to determine the potential neutralizing activity of the ADA | Week 120 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |